John D Gentry, MD | |
8303 Dodge St, Omaha, NE 68114-4108 | |
(402) 354-4540 | |
(402) 354-4535 |
Full Name | John D Gentry |
---|---|
Gender | Male |
Speciality | Pathology |
Experience | 22 Years |
Location | 8303 Dodge St, Omaha, Nebraska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1477642205 | NPI | - | NPPES |
47037660422 | Medicaid | NE | |
1477642205 | Medicaid | IA | |
404408000 | Medicaid | MN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 23727 (Nebraska) | Primary |
207ZP0101X | Pathology - Anatomic Pathology | 48894 (Minnesota) | Secondary |
Facility Name | Location | Facility Type |
---|---|---|
The Nebraska Methodist Hospital | Omaha, NE | Hospital |
Methodist Fremont Health | Fremont, NE | Hospital |
Montgomery County Memorial Hospital | Red oak, IA | Hospital |
Saunders Medical Center | Wahoo, NE | Hospital |
Lexington Regional Health Center | Lexington, NE | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Nebraska Methodist Hospital | 6901707447 | 118 |
Methodist Fremont Health | 7911258520 | 67 |
Jennie Edmundson Memorial Hospital | 9537064837 | 32 |
News Archive
The nervous system is the body's control center, which is extremely fast in decoding messages from the different nerves in the body. This network should be intact and healthy. When something is wrong with the network, it affects the brain's main functions.
Relievant Medsystems, Inc., a privately held medical device company pioneering the therapeutic use of basivertebral nerve ablation for the treatment of chronic axial low back pain, announced today that it has secured $30 million in a Series D equity financing to advance and expand the Company's worldwide clinical development programs.
UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.
The International Society for Cellular Therapy, the global society of clinicians, researchers, regulatory specialists, technologists, and industry partners dedicated to the translation of cellular therapy into safe and effective therapies to improve patients' lives, today announces its reasons for opposition to the current version of the REGROW Act - the US government's legislative efforts to promote faster patient access to effective new cellular therapies.
› Verified 9 days ago
Entity Name | Nebraska Methodist Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1689628372 PECOS PAC ID: 6901707447 Enrollment ID: O20040116000781 |
News Archive
The nervous system is the body's control center, which is extremely fast in decoding messages from the different nerves in the body. This network should be intact and healthy. When something is wrong with the network, it affects the brain's main functions.
Relievant Medsystems, Inc., a privately held medical device company pioneering the therapeutic use of basivertebral nerve ablation for the treatment of chronic axial low back pain, announced today that it has secured $30 million in a Series D equity financing to advance and expand the Company's worldwide clinical development programs.
UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.
The International Society for Cellular Therapy, the global society of clinicians, researchers, regulatory specialists, technologists, and industry partners dedicated to the translation of cellular therapy into safe and effective therapies to improve patients' lives, today announces its reasons for opposition to the current version of the REGROW Act - the US government's legislative efforts to promote faster patient access to effective new cellular therapies.
› Verified 9 days ago
Entity Name | Methodist Fremont Health |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1235618216 PECOS PAC ID: 7911258520 Enrollment ID: O20181017000110 |
News Archive
The nervous system is the body's control center, which is extremely fast in decoding messages from the different nerves in the body. This network should be intact and healthy. When something is wrong with the network, it affects the brain's main functions.
Relievant Medsystems, Inc., a privately held medical device company pioneering the therapeutic use of basivertebral nerve ablation for the treatment of chronic axial low back pain, announced today that it has secured $30 million in a Series D equity financing to advance and expand the Company's worldwide clinical development programs.
UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.
The International Society for Cellular Therapy, the global society of clinicians, researchers, regulatory specialists, technologists, and industry partners dedicated to the translation of cellular therapy into safe and effective therapies to improve patients' lives, today announces its reasons for opposition to the current version of the REGROW Act - the US government's legislative efforts to promote faster patient access to effective new cellular therapies.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
John D Gentry, MD Po Box 2797, Omaha, NE 68103-2797 Ph: (402) 354-4230 | John D Gentry, MD 8303 Dodge St, Omaha, NE 68114-4108 Ph: (402) 354-4540 |
News Archive
The nervous system is the body's control center, which is extremely fast in decoding messages from the different nerves in the body. This network should be intact and healthy. When something is wrong with the network, it affects the brain's main functions.
Relievant Medsystems, Inc., a privately held medical device company pioneering the therapeutic use of basivertebral nerve ablation for the treatment of chronic axial low back pain, announced today that it has secured $30 million in a Series D equity financing to advance and expand the Company's worldwide clinical development programs.
UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.
The International Society for Cellular Therapy, the global society of clinicians, researchers, regulatory specialists, technologists, and industry partners dedicated to the translation of cellular therapy into safe and effective therapies to improve patients' lives, today announces its reasons for opposition to the current version of the REGROW Act - the US government's legislative efforts to promote faster patient access to effective new cellular therapies.
› Verified 9 days ago
Audrey J Lazenby, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: Emile @ 42nd St, Omaha, NE 68198 Phone: 402-559-4186 Fax: 402-559-6018 | |
Shane K. Kohl, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 8303 Dodge St, Omaha, NE 68114 Phone: 402-354-4540 Fax: 402-354-4535 | |
Stanley J Radio, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 988102 Nebraska Medical Ctr, Omaha, NE 68198 Phone: 402-559-4186 Fax: 402-559-6018 | |
Christine Petricek Hans, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 8303 Dodge St, Omaha, NE 68114 Phone: 402-354-4540 Fax: 402-354-4535 | |
Dr. Diana L Nevins, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 8303 Dodge St, Omaha, NE 68114 Phone: 402-354-4540 Fax: 402-354-4535 | |
Dr. Marc R Hapke, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 909 N 96th St, Suite 201, Omaha, NE 68114 Phone: 402-330-4555 Fax: 402-934-0945 | |
Bryan Scott Teruya, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 4101 Woolworth Ave, Department Of Pathology, Omaha, NE 68105 Phone: 402-995-3218 |